Prathima Jasti, MD
Endocrinology, Diabetes & Metabolism · Lincoln, NENPI 1699971473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 30.4% of the total. 2025 is the largest year on record at $308, 2.7 times the $114 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NE, where the typical reported total is $1,422.
Across 61 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$360
- Medtronic$125
- Tandem Diabetes Care, Inc.$100
- Dexcom, Inc.$89
- Amgen$72
- Insulet Corporation$63
- plus $375 from 13 others
What the payments were for
- Food & beverage$1,184100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $360 |
| Medtronic(2 entities) | 7 | $125 |
| Tandem Diabetes Care, Inc. | 6 | $100 |
| Dexcom, Inc. | 6 | $89 |
| Amgen | 4 | $72 |
| Insulet Corporation | 3 | $63 |
| Corcept Therapeutics | 1 | $60 |
| Boehringer Ingelheim | 3 | $52 |
| Lilly USA, LLC | 3 | $41 |
| AstraZeneca | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Ascendis Pharma Endocrinology Inc | 2 | $28 |
| AbbVie | 1 | $24 |
| Abbott | 1 | $23 |
| Ardelyx, Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $13 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
| Bayer | 1 | $13 |
| Tolmar, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$122
How this compares
$1,184 in reported general payments places this provider in the 40th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 496 | $560,940 |
| JardianceEmpagliflozin | 232 | $205,897 |
| TrulicityDulaglutide | 129 | $183,632 |
| Tresiba Flextouch U-200Insulin Degludec | 176 | $175,904 |
| FarxigaDapagliflozin Propanediol | 117 | $121,149 |
| Humalog Kwikpen U-200Insulin Lispro | 73 | $104,959 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $60,416 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $55,045 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 66 | $45,582 |
| MounjaroTirzepatide | 35 | $44,381 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $43,015 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $40,003 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $35,248 |
| Humalog Kwikpen U-100Insulin Lispro | 114 | $30,160 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 73 | $29,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $360 | $566,986512 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $52 | $265,427298 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $41 | $228,012164 claims |
| AstraZenecaFarxiga | $36 | $121,149117 claims |
| AbbVieSynthroid | $24 | $10,464130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Lincoln
- Shannon WakeleyLincoln$78K
- Madeline Jones RyanLincoln$4K
- Kara Meinke BaehrLincoln$1K
- Jalal NafachLincoln$110
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.